ContraFect Corporation
| NASDAQ: CFRX | Healthcare / Biotechnology / USA |
| 4.09 | -0.0200 | -0.49% | Vol 145.56K | 1Y Perf -38.87% |
| Apr 19th, 2021 10:42 DELAYED |
| BID | 4.09 | ASK | 4.11 | ||
| Open | 4.05 | Previous Close | 4.11 | ||
| Pre-Market | 4.01 | After-Market | - | ||
| -0.10 -2.43% | - - |
| Target Price | 16.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 294.09 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 160.87M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 5.56 | Earnings Date | 21st May 2021 |
Today's Price Range 4.004.16 | 52W Range 3.868.00 | 5 Year PE Ratio Range -3.40-2.90 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -1.91% | ||
| 1 Month | -33.92% | ||
| 3 Months | -20.50% | ||
| 6 Months | -23.61% | ||
| 1 Year | -38.87% | ||
| 3 Years | -74.79% | ||
| 5 Years | -89.10% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -130.05 | |||
ROE last 12 Months | -190.60 | |||
ROA (5Y Avg) | -58.75 | |||
ROA last 12 Months | -63.11 | |||
ROC (5Y Avg) | -129.59 | |||
ROC last 12 Months | -213.41 | |||
Return on invested Capital Q | -33.65 | |||
Return on invested Capital Y | -158.97 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.40 | ||||
| 13.43 | ||||
| - | ||||
| - | ||||
| -6.60 | ||||
| -1.46 | ||||
| 13.43 | ||||
| 0.32 | ||||
| 130.64M | ||||
| Forward PE | -4.06 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 7.00 | ||||
| 7.70 | ||||
| 0.19 | ||||
| 0.29 | ||||
| - | ||||
| Leverage Ratio | 4.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.28 | -0.52 | -85.71 |
| Q03 2020 | -0.27 | -0.19 | 29.63 |
| Q02 2020 | -0.33 | -0.47 | -42.42 |
| Q01 2020 | -0.65 | -0.49 | 24.62 |
| Q04 2019 | -0.84 | 0.88 | 204.76 |
| Q03 2019 | -0.90 | -0.70 | 22.22 |
| Q02 2019 | -0.90 | -0.90 | 0.00 |
| Q01 2019 | -1.00 | 1.50 | 250.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.26 | 84.34 | Positive |
| 6/2021 QR | -0.22 | 78.64 | Positive |
| 12/2021 FY | -1.50 | - | - |
| 12/2022 FY | -1.02 | - | - |
| Next Report Date | 21st May 2021 |
| Estimated EPS Next Report | -0.26 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 145.56K |
| Shares Outstanding | 39.33M |
| Trades Count | 640 |
| Dollar Volume | 974.22K |
| Avg. Volume | 982.77K |
| Avg. Weekly Volume | 557.20K |
| Avg. Monthly Volume | 1.21M |
| Avg. Quarterly Volume | 1.13M |
ContraFect Corporation (NASDAQ: CFRX) stock closed at 4.11 per share at the end of the most recent trading day (a 2.24% change compared to the prior day closing price) with a volume of 580.09K shares and market capitalization of 160.87M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. ContraFect Corporation CEO is Roger J. Pomerantz.
The one-year performance of ContraFect Corporation stock is -38.87%, while year-to-date (YTD) performance is -18.61%. CFRX stock has a five-year performance of -89.1%. Its 52-week range is between 3.86 and 8, which gives CFRX stock a 52-week price range ratio of 5.56%
ContraFect Corporation currently has a PE ratio of -2.40, a price-to-book (PB) ratio of 13.43, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -63.11%, a ROC of -213.41% and a ROE of -190.60%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from ContraFect Corporation, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. ContraFect Corporation’s next earnings report date is 21st May 2021.
The consensus rating of Wall Street analysts for ContraFect Corporation is Strong Buy (1), with a target price of $16, which is +294.09% compared to the current price. The earnings rating for ContraFect Corporation stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ContraFect Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ContraFect Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 16.05, ATR14 : 0.35, CCI20 : -103.26, Chaikin Money Flow : -0.09, MACD : -0.42, Money Flow Index : 27.20, ROC : -8.26, RSI : 40.24, STOCH (14,3) : 22.32, STOCH RSI : 1.00, UO : 47.45, Williams %R : -77.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ContraFect Corporation in the last 12-months were:
ContraFect Corporation
ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
CEO: Roger J. Pomerantz
Telephone: +1 914 207-2300
Address: 28 Wells Avenue, Yonkers 10701, NY, US
Number of employees: 24
